Private Label Body Products: When Your Order Becomes a Drug
Most private label body products are cosmetics under US law, and the rules are relatively light. But body care crosses into drug territory most easily, because deodorant, body wash and body lotion each sit one claim or one active ingredient from the FDA’s drug definition. If your deodorant reduces sweat rather than masking odor, or your body wash is sold as killing germs, it is a drug, and the requirements change before a unit is filled.
That distinction decides your label format, ingredient caps, registration path and manufacturing standard. Better settled at the brief stage than after a fill run.
What makes a body product a cosmetic
The Federal Food, Drug, and Cosmetic Act defines cosmetics as articles applied to the body “for cleansing, beautifying, promoting attractiveness, or altering the appearance” (sec. 201(i)), and the FDA’s guidance names deodorants explicitly. A body lotion that moisturizes, a scrub that exfoliates the look of skin, a deodorant that addresses odor — all cosmetics.
A drug, by contrast, is anything intended for “the diagnosis, cure, mitigation, treatment, or prevention of disease,” or intended “to affect the structure or any function of the body” (sec. 201(g)(1)). That second half is the one founders miss: it has nothing to do with disease. Changing how the body works is enough.
Deodorant versus antiperspirant is the clearest example
A deodorant works on odor and is a cosmetic. An antiperspirant reduces sweating, a bodily function, so it is a drug. 21 CFR 350.3 defines an antiperspirant as “a drug product applied topically that reduces the production of perspiration (sweat) at that site.”
That brings a fixed rulebook. Active ingredients are limited to specified aluminum and aluminum-zirconium salts at capped concentrations — aluminum chloride up to 15 percent in an aqueous nonaerosol form, aluminum chlorohydrate up to 25 percent, aluminum zirconium tetrachlorohydrex gly up to 20 percent (21 CFR 350.10). The label must identify the product as an “antiperspirant,” warn “Do not use on broken skin,” and direct “apply to underarms only” (21 CFR 350.50). Under the deemed final order for monograph M019, 20 percent sweat reduction over 24 hours supports a standard effectiveness claim and 30 percent an extra effectiveness claim, and no product in that monograph may claim longer than 24 hours. A product that is both deodorant and antiperspirant has to satisfy both rulebooks at once.
Body wash, soap and the three-condition test
Soap is a separate case, and the legal meaning is narrower than the everyday one. The FDA applies the term only when the nonvolatile bulk is alkali salts of fatty acids, the detergent action comes from those compounds, and the product is labeled, sold and represented solely as soap (21 CFR 701.20). Products meeting all three sit outside the FD&C Act and fall to the Consumer Product Safety Commission.
Almost no modern private label body wash qualifies. Synthetic detergents make it a cosmetic. Marketing it as moisturizing, fragrancing or deodorizing makes it a cosmetic even if it is true soap chemically. Market it as killing germs, or add an acne active, and the FDA treats it as a drug or as both. You can still print the word “soap” on the label in every one of those cases — the word is not what decides it.
What changes once it is a drug
- Clearance. Cosmetic products and ingredients need no FDA premarket clearance except color additives. An OTC drug must conform to a monograph or hold an approved New Drug Application.
- Manufacturing standard. Drug GMP is already mandatory under 21 CFR 210 and 211. Cosmetic GMP under MoCRA is still pending as a final rule.
- Labeling. OTC drugs require a “Drug Facts” panel (21 CFR 201.66). A combination drug/cosmetic lists drug ingredients alphabetically as “Active Ingredients,” then cosmetic ingredients by descending predominance as “Inactive.”
- Registration. Drug establishments register and list under FD&C Act sec. 510 and 21 CFR 207. MoCRA separately requires cosmetic facility registration renewed every two years and listings updated annually; per the Congressional Research Service, cosmetic/drug combinations are treated as drugs for listing purposes.
- Who files. The responsible person is whoever’s name is on the label (FD&C Act sec. 609(a)) — your brand, not the factory. And the FDA does not issue certificates verifying facility registration, so no one can send you one.
How to brief it so the line is decided up front
Write the claim you intend to sell on before you pick the formula. “Stays fresh all day” and “blocks sweat for 24 hours” are different products with different label formats, not two ways of saying the same thing. The FDA treats intended use as established by your labeling, advertising and website, by consumer perception, and by ingredients with a well-known therapeutic use — so marketing copy can convert a cosmetic into an unapproved drug without the formula changing at all. There is also no legal category called a “cosmeceutical”: a product is a cosmetic, a drug, or both.
Bring the claim and the category to the quoting stage. At Moe’s Group, formulation, filling and labeling happen in one FDA-registered facility in Chatsworth, California, across skincare, hair care and body care: ready-to-go white label formulas start at 200 units, custom formulations at 1,000.
Scoping a body care line and unsure which side of the line your claim falls on? Send us the brief and we will tell you what the category requires.
Moe’s Group Newsroom
